Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
20 August 2018 |
Main ID: |
EUCTR2015-005170-38-LV |
Date of registration:
|
25/07/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study of efficacy and safety of secukinumab 2 mL pre-filled syringe (300 mg) in subjects with moderate to severe plaque psoriasis
|
Scientific title:
|
A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (300 mg) in adUlt subjects with moderate to seveRE plaque psoriasis – ALLURE
- ALLURE |
Date of first enrolment:
|
22/09/2016 |
Target sample size:
|
210 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005170-38 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: yes Other: no Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Canada
|
Germany
|
Iceland
|
Latvia
|
Poland
|
Russian Federation
|
Spain
|
Turkey
|
United Kingdom
|
United States
| | | | | |
Contacts
|
Name:
|
Irena Feldmane
|
Address:
|
Ropazu street 10
LV-1039
Riga
Latvia |
Telephone:
|
+37167887070 |
Email:
|
irena.feldmane@novartis.com |
Affiliation:
|
Novartis Pharma Services Reprezentative Office |
|
Name:
|
Irena Feldmane
|
Address:
|
Ropazu street 10
LV-1039
Riga
Latvia |
Telephone:
|
+37167887070 |
Email:
|
irena.feldmane@novartis.com |
Affiliation:
|
Novartis Pharma Services Reprezentative Office |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: * Men or women of at least 18 years of age at the time of Screening.
* Moderate to severe chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
* Candidate for systemic therapy.
* Additional inclusion criteria may apply , please refer to the protocol. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 189 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 21
Exclusion criteria: * Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis)
* Ongoing use of prohibited treatments.
* Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
* Pregnant or nursing (lactating) women
*Additional exclusion criteria may apply , please refer to the protocol.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Plaque psoriasis MedDRA version: 19.0
Level: LLT
Classification code 10050576
Term: Psoriasis vulgaris
System Organ Class: 100000004858
|
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
|
Intervention(s)
|
Trade Name: COSENTYX Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Secukinumab CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Other descriptive name: SECUKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use
Trade Name: COSENTYX Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Secukinumab CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Other descriptive name: SECUKINUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use
|
Primary Outcome(s)
|
Primary end point(s): PASI 75 and IGA mod 2011 0 or 1 response
|
Secondary Objective: • To demonstrate the efficacy of secukinumab 300 mg when administered as 2 mL pre-filled syringes in subjects with chronic plaque-type psoriasis with respect to PASI 90 and PASI 100 at Week 12, compared to placebo. • To demonstrate the efficacy of secukinumab 300 mg when administered as two 1 mL pre-filled syringes in subjects with chronic plaque-type psoriasis with respect to PASI 100 at Week 12, compared to placebo.
|
Timepoint(s) of evaluation of this end point: Week 12
|
Main Objective: To demonstrate the efficacy of secukinumab 300 mg when administered as 2 mL pre-filled syringes in subjects with chronic plaque-type psoriasis with respect to both PASI 75 and IGA mod 2011 0 or 1 response (co-primary endpoint) at Week 12, compared to placebo.
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Week 12
|
Secondary end point(s): PASI 90 and PASI 100
|
Secondary ID(s)
|
CAIN457A2323
|
2015-005170-38-GB
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|